Devi's Custom Synthesis - Should Investors Be Worried?

2min Snip

00:00

Play full episode

Summary

Transcript

Episode notes

Devi's custom synthetic share had jumped to nearly 60% of its business in FY 22, it has fallen back again to just 40%. Investors were disappointed. They had bought the stock in anticipation that these good times will continue. And the thing is, Devi's custom synthesis business isn't in its control. The pharma giants actively creating new drugs and running clinical trials ebbs and flows. It's not immune to short term variations.

In today's episode for 11th February 2023, we see what's really happening at Divi's laboratories.

We're now on YouTube. But not as Finshots.

Instead, get ready for a fresh perspective on finance with the beloved curator and co-founder of Finshots' - Shrehith Karkera where he deep dives into the world of finance completely unfiltered.

In our latest video, we cover how startup scams happen and explore the dark side of entrepreneurship.

Tune in now to Shrehith Karkera (https://youtube.com/@shrehithskarkera) on YouTube and don’t forget to subscribe to stay ahead of the game in finance.